The FCF Healthcare & Life Sciences Venture Capital Monitor – USA is a monthly overview of funding trends in the venture capital sector, with a focus on U.S. healthcare and life sciences companies.
Total Healthcare & Life Sciences funding reached EUR 19,218m (-8% vs. 2025)
Biotech/Pharma received 40% of the total investment volume (EUR 7,755m), with oncology being the leading indication (30%)
In June, NewLimit secured the highest transaction volume with EUR 373m, followed by Ollin with EUR 285m and Beren Therapeutics with EUR 258m
Boston Scientific (United States) is the most active investor (by deal volume in 2026), followed by RA Capital Management (United States) and Lightspeed Venture Partners (United States)
To read the full report, click here.